ONCAlert | Upfront Therapy for mRCC

Analyzing the Survival Benefits of Niraparib Dose Modification in Ovarian Cancer

Ursula A. Matulonis, MD
Published Online: 1:43 PM, Tue March 19, 2019

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the survival results from an analysis of the QUADRA trial in heavily pretreated patients with recurrent ovarian cancer.

Patients with a platelet count greater than 150 and a body weight over 77 kg received a starting dose of niraparib (Zejula) at 200 mg. In this group, overall survival (OS) was a little less than those who were started at 300 mg, Matulonis says.

In patients with platelet counts less than 150 and weighing less than 77 kg, the OS was comparable to that of the 300 mg dose. This suggests that physicians should consider starting at a 300 mg dose for patients with a body weight greater than 77 kg and platelet counts greater than 150, Matulonis concludes.

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.